Spots Global Cancer Trial Database for Trial of Iressa in Prostate Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial of Iressa in Prostate Cancer Patients
Official Title: An Open-Label, Phase II Trial Of 250 mg ZD1839 (IRESSA™) In Prostate Cancer Patients With Early Biochemical Failure Post Prostatectomy
Study ID: NCT00265070
Conditions
Interventions
Study Description
Brief Summary: This study is being carried out to see if ZD1839 is effective in treating prostate cancer after being diagnosed with an early rising PSA (prostate specific antigen) following surgery.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Research Site, Vancouver, British Columbia, Canada
Research Site, London, Ontario, Canada
Research Site, Toronto, Ontario, Canada
Research Site, Montreal, , Canada
Contact Details
Name: AstraZeneca Canada Oncology Medical Director, MD
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
